Don’t forget that Pasaca/Innova got their hands

Don’t forget that Pasaca/Innova got their hands a slapped y the FDA for marketing tests in the U.S. without FDA approval. They are in the FDA’s dog house and might feel pretty discouraged about the chances of the FDA approving their test, or at least approving enforce it approves all other tests, effectively putting Pasaca/Innova at the back of the line worth the smallest market share. In that case, Pasaca may well see QTMM’s monumental display of incompetence as an opportunity to back out of what may be shaping up to be an unprofitable enterprise for Pasaca in the U.S. Puravida, do me a favor, when you return this post with the usual plethora of highly speculative hypothetical scenarios, to help us distinguish between what’s real and what is wishful thinking, please specify how much income QTMM has reported in connection with any of the developments you outline. That way we’ll be able to tell the difference between what has actually happened and wishful thinking.